Groupama Asset Managment Purchases 681 Shares of Stryker Co. (NYSE:SYK)

Groupama Asset Managment increased its position in shares of Stryker Co. (NYSE:SYK) by 51.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,007 shares of the medical technology company’s stock after buying an additional 681 shares during the period. Groupama Asset Managment’s holdings in Stryker were worth $727,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Edgestream Partners L.P. lifted its position in shares of Stryker by 216.1% during the 3rd quarter. Edgestream Partners L.P. now owns 3,430 shares of the medical technology company’s stock worth $1,239,000 after purchasing an additional 2,345 shares during the last quarter. Ascent Group LLC lifted its holdings in shares of Stryker by 2.0% during the third quarter. Ascent Group LLC now owns 3,867 shares of the medical technology company’s stock worth $1,397,000 after buying an additional 77 shares during the last quarter. Hilltop Holdings Inc. grew its stake in shares of Stryker by 161.2% in the third quarter. Hilltop Holdings Inc. now owns 3,479 shares of the medical technology company’s stock worth $1,257,000 after acquiring an additional 2,147 shares during the last quarter. Investment Management Corp of Ontario grew its stake in shares of Stryker by 26.0% in the third quarter. Investment Management Corp of Ontario now owns 17,945 shares of the medical technology company’s stock worth $6,483,000 after acquiring an additional 3,700 shares during the last quarter. Finally, Integrated Wealth Concepts LLC increased its position in Stryker by 1.0% during the third quarter. Integrated Wealth Concepts LLC now owns 5,629 shares of the medical technology company’s stock worth $2,034,000 after acquiring an additional 54 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Up 1.2 %

Shares of SYK opened at $377.82 on Thursday. The company has a market capitalization of $144.21 billion, a P/E ratio of 48.69, a PEG ratio of 2.93 and a beta of 0.95. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The business’s 50 day simple moving average is $383.16 and its 200-day simple moving average is $374.45. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the company earned $3.46 EPS. As a group, sell-side analysts predict that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.89%. Stryker’s payout ratio is 43.30%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on SYK. Stifel Nicolaus increased their price target on shares of Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. StockNews.com cut shares of Stryker from a “buy” rating to a “hold” rating in a research note on Thursday, March 6th. Royal Bank of Canada upped their price target on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. Needham & Company LLC reissued a “buy” rating and set a $442.00 price objective on shares of Stryker in a report on Friday, March 21st. Finally, Canaccord Genuity Group upped their target price on Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $421.90.

Insider Activity

In other news, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.50% of the stock is owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.